{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T21:58:43Z","timestamp":1778623123549,"version":"3.51.4"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,7,19]],"date-time":"2021-07-19T00:00:00Z","timestamp":1626652800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,7,19]],"date-time":"2021-07-19T00:00:00Z","timestamp":1626652800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Lung"],"published-print":{"date-parts":[[2021,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>This review discusses how the placebo effect related to treatment side effects may confound clinical trials on antitussives and specifically looks at the implications for trials on ATP antagonists. These new antitussives have distinctive side effects on the sensation of taste, and investigators have expressed concerns that this may unblind the clinical trials. Blinding is an essential component of trial design, but the degree of blinding in trials is rarely assessed. The assumptions of additivity and balance in clinical trials are discussed as important factors that allow assessment of the pharmacological activity of an antitussive. How side effects unbalance a clinical trial by amplifying the placebo effect of active treatments is discussed. The point is made that unblinding of trials invalidates any assessment of efficacy but that there is little interest or discussion about this fundamental aspect of trials. Proposals are discussed which may improve the blinding of trials and control placebo effects by changes to participant information, trial design, patient selection and use of active placebos. The issue of unblinding of clinical trials is not a new issue, but if real progress is to be made in developing new antitussives, then it is an issue that needs to be urgently addressed.<\/jats:p>","DOI":"10.1007\/s00408-021-00458-2","type":"journal-article","created":{"date-parts":[[2021,7,19]],"date-time":"2021-07-19T07:02:52Z","timestamp":1626678172000},"page":"319-326","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Placebo and Side Effects Confound Clinical Trials on New Antitussives"],"prefix":"10.1007","volume":"199","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9492-2062","authenticated-orcid":false,"given":"Ronald","family":"Eccles","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,7,19]]},"reference":[{"issue":"2","key":"458_CR1","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1124\/pr.111.005116","volume":"66","author":"PV Dicpinigaitis","year":"2014","unstructured":"Dicpinigaitis PV et al (2014) Antitussive drugs\u2013past, present, and future. Pharmacol Rev 66(2):468\u2013512","journal-title":"Pharmacol Rev"},{"issue":"3","key":"458_CR2","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1006\/pupt.2002.0365","volume":"15","author":"PC Lee","year":"2002","unstructured":"Lee PC, Cotterill-Jones C, Eccles R (2002) Voluntary control of cough. Pulm Pharmacol Ther 15(3):317\u2013320","journal-title":"Pulm Pharmacol Ther"},{"key":"458_CR3","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/978-3-540-79842-2_13","volume":"187","author":"PW Davenport","year":"2009","unstructured":"Davenport PW (2009) Clinical cough I: the urge-to-cough: a respiratory sensation. Handb Exp Pharmacol 187:263\u2013276","journal-title":"Handb Exp Pharmacol"},{"issue":"1","key":"458_CR4","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.chest.2020.08.2086","volume":"159","author":"KK Lee","year":"2021","unstructured":"Lee KK et al (2021) Global physiology and pathophysiology of cough: part 1: cough phenomenology-CHEST guideline and expert panel report. Chest 159(1):282\u2013293","journal-title":"Chest"},{"issue":"5","key":"458_CR5","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1111\/j.1600-0447.1976.tb00082.x","volume":"53","author":"JL Marini","year":"1976","unstructured":"Marini JL, Sheard MH, Bridges CI, Wagner E (1976) An evaluation of the double-blind design in a study comparing lithium carbonate with placebo. Acta Psychiatr Scand 53(5):343\u2013354","journal-title":"Acta Psychiatr Scand"},{"key":"458_CR6","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1192\/bjp.140.1.64","volume":"140","author":"R Thomson","year":"1982","unstructured":"Thomson R (1982) Side effects and placebo amplification. Br J Psychiatry 140:64\u201368","journal-title":"Br J Psychiatry"},{"issue":"6","key":"458_CR7","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1097\/00005053-199306000-00002","volume":"181","author":"S Fisher","year":"1993","unstructured":"Fisher S, Greenberg RP (1993) How sound is the double-blind design for evaluating psychotropic drugs? J Nerv Ment Dis 181(6):345\u2013350","journal-title":"J Nerv Ment Dis"},{"issue":"5","key":"458_CR8","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.jpain.2018.09.002","volume":"20","author":"B Colagiuri","year":"2019","unstructured":"Colagiuri B, Sharpe L, Scott A (2019) The blind leading the not-so-blind: a meta-analysis of blinding in pharmacological trials for chronic pain. J Pain 20(5):489\u2013500","journal-title":"J Pain"},{"issue":"8","key":"458_CR9","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/S2213-2600(19)30471-0","volume":"8","author":"JA Smith","year":"2020","unstructured":"Smith JA et al (2020) Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: a randomised, double-blind, controlled, parallel-group, phase 2b trial. Lancet Respir Med 8(8):775\u2013785","journal-title":"Lancet Respir Med"},{"issue":"4","key":"458_CR10","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1007\/s00408-020-00377-8","volume":"198","author":"PV Dicpinigaitis","year":"2020","unstructured":"Dicpinigaitis PV, McGarvey LP, Canning BJ (2020) P2X3-Receptor antagonists as potential antitussives: summary of current clinical trials in chronic cough. Lung 198(4):609\u2013616","journal-title":"Lung"},{"issue":"6","key":"458_CR11","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1002\/cpt.1626","volume":"106","author":"KT Hall","year":"2019","unstructured":"Hall KT, Loscalzo J (2019) Drug-placebo additivity in randomized clinical trials. Clin Pharmacol Ther 106(6):1191\u20131197","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"458_CR12","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/clpt.1987.26","volume":"41","author":"M Moscucci","year":"1987","unstructured":"Moscucci M, Byrne L, Weintraub M, Cox C (1987) Blinding, unblinding, and the placebo effect: an analysis of patients\u2019 guesses of treatment assignment in a double-blind clinical trial. Clin Pharmacol Ther 41(3):259\u2013265","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"458_CR13","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1177\/1740774510367916","volume":"7","author":"B Colagiuri","year":"2010","unstructured":"Colagiuri B (2010) Participant expectancies in double-blind randomized placebo-controlled trials: potential limitations to trial validity. Clin Trials 7(3):246\u2013255","journal-title":"Clin Trials"},{"issue":"1","key":"458_CR14","first-page":"1a","volume":"6","author":"F Benedetti","year":"2003","unstructured":"Benedetti F, Maggi G, Lopiano L (2003) Open versus hidden medical treatments: the patient\u2019s knowledge about a therapy affects the therapy outcome. Prevent Treat 6(1):1a","journal-title":"Prevent Treat"},{"issue":"5","key":"458_CR15","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1007\/s00408-020-00390-x","volume":"198","author":"R Eccles","year":"2020","unstructured":"Eccles R (2020) What is the role of over 100 excipients in over the counter (OTC) cough medicines? Lung 198(5):727\u2013734","journal-title":"Lung"},{"key":"458_CR16","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/bs.irn.2018.07.014","volume":"139","author":"K Meissner","year":"2018","unstructured":"Meissner K, Linde K (2018) Are blue pills better than green? how treatment features modulate placebo effects. Int Rev Neurobiol 139:357\u2013378","journal-title":"Int Rev Neurobiol"},{"issue":"1","key":"458_CR17","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s00408-019-00305-5","volume":"198","author":"R Eccles","year":"2020","unstructured":"Eccles R (2020) The powerful placebo effect in cough: relevance to treatment and clinical trials. Lung 198(1):13\u201321","journal-title":"Lung"},{"issue":"2","key":"458_CR18","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1007\/s11882-007-0006-2","volume":"7","author":"R Eccles","year":"2007","unstructured":"Eccles R (2007) The power of the placebo. Curr Allergy Asthma Rep 7(2):100\u2013104","journal-title":"Curr Allergy Asthma Rep"},{"key":"458_CR19","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1136\/bmj.311.7004.551","volume":"311","author":"E Ernst","year":"1995","unstructured":"Ernst E, Resch KL (1995) Concept of true and perceived placebo effects. BMJ 311:551\u2013553","journal-title":"BMJ"},{"issue":"6","key":"458_CR20","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1097\/j.pain.0000000000000870","volume":"158","author":"C Berna","year":"2017","unstructured":"Berna C et al (2017) Side effects can enhance treatment response through expectancy effects: an experimental analgesic randomized controlled trial. Pain 158(6):1014\u20131020","journal-title":"Pain"},{"key":"458_CR21","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/bs.irn.2018.01.003","volume":"138","author":"I Kirsch","year":"2018","unstructured":"Kirsch I (2018) Response expectancy and the placebo effect. Int Rev Neurobiol 138:81\u201393","journal-title":"Int Rev Neurobiol"},{"issue":"5","key":"458_CR22","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1097\/00001756-199904060-00037","volume":"10","author":"X Bo","year":"1999","unstructured":"Bo X et al (1999) Localization of ATP-gated P2X2 and P2X3 receptor immunoreactive nerves in rat taste buds. NeuroReport 10(5):1107\u20131111","journal-title":"NeuroReport"},{"issue":"9974","key":"458_CR23","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1016\/S0140-6736(14)61255-1","volume":"385","author":"R Abdulqawi","year":"2015","unstructured":"Abdulqawi R et al (2015) P2X3 receptor antagonist (AF-219) in refractory chronic cough: a randomised, double-blind, placebo-controlled phase 2 study. Lancet 385(9974):1198\u20131205","journal-title":"Lancet"},{"issue":"1","key":"458_CR24","doi-asserted-by":"publisher","first-page":"1900439","DOI":"10.1183\/13993003.00439-2019","volume":"54","author":"AH Morice","year":"2019","unstructured":"Morice AH et al (2019) The effect of gefapixant, a P2X3 antagonist, on cough reflex sensitivity: a randomised placebo-controlled study. Eur Respir J 54(1):1900439","journal-title":"Eur Respir J"},{"key":"458_CR25","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01615-2019","author":"JA Smith","year":"2020","unstructured":"Smith JA et al (2020) Gefapixant in two randomised dose-escalation studies in chronic cough. Eur Respir J. https:\/\/doi.org\/10.1183\/13993003.01615-2019","journal-title":"Eur Respir J"},{"key":"458_CR26","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.pupt.2019.03.007","volume":"56","author":"D Garceau","year":"2019","unstructured":"Garceau D, Chauret N (2019) BLU-5937: a selective P2X3 antagonist with potent anti-tussive effect and no taste alteration. Pulm Pharmacol Ther 56:56\u201362","journal-title":"Pulm Pharmacol Ther"},{"issue":"3","key":"458_CR27","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1080\/15265161.2011.652798","volume":"12","author":"RE Wells","year":"2012","unstructured":"Wells RE, Kaptchuk TJ (2012) To tell the truth, the whole truth, may do patients harm: the problem of the nocebo effect for informed consent. Am J Bioeth 12(3):22\u201329","journal-title":"Am J Bioeth"},{"issue":"8","key":"458_CR28","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1007\/s00115-020-00963-4","volume":"91","author":"E Hansen","year":"2020","unstructured":"Hansen E, Zech N, Benson S (2020) Nocebo, informed consent and doctor-patient communication. Nervenarzt 91(8):691\u2013699","journal-title":"Nervenarzt"},{"issue":"3","key":"458_CR29","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1111\/j.1467-8519.2012.01983.x","volume":"28","author":"S Cohen","year":"2014","unstructured":"Cohen S (2014) The nocebo effect of informed consent. Bioethics 28(3):147\u2013154","journal-title":"Bioethics"},{"issue":"1","key":"458_CR30","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1017\/S0963180108080079","volume":"17","author":"BN Waller","year":"2008","unstructured":"Waller BN, Repko RA (2008) Informed consent: good medicine, dangerous side effects. Camb Q Healthc Ethics 17(1):66\u201374","journal-title":"Camb Q Healthc Ethics"},{"issue":"5","key":"458_CR31","first-page":"385","volume":"49","author":"TR Weihrauch","year":"1999","unstructured":"Weihrauch TR, Gauler TC (1999) Placebo\u2013efficacy and adverse effects in controlled clinical trials. Arzneimittelforschung 49(5):385\u2013393","journal-title":"Arzneimittelforschung"},{"key":"458_CR32","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.jclinepi.2017.03.001","volume":"87","author":"JS Jensen","year":"2017","unstructured":"Jensen JS, Bielefeldt AO, Hrobjartsson A (2017) Active placebo control groups of pharmacological interventions were rarely used but merited serious consideration: a methodological overview. J Clin Epidemiol 87:35\u201346","journal-title":"J Clin Epidemiol"},{"issue":"Suppl 1","key":"458_CR33","doi-asserted-by":"publisher","first-page":"S53","DOI":"10.1007\/s00408-009-9173-3","volume":"188","author":"R Eccles","year":"2010","unstructured":"Eccles R (2010) Importance of placebo effect in cough clinical trials. Lung 188(Suppl 1):S53-61","journal-title":"Lung"},{"issue":"3","key":"458_CR34","doi-asserted-by":"publisher","first-page":"e026478","DOI":"10.1136\/bmjopen-2018-026478","volume":"9","author":"HB Krogh","year":"2019","unstructured":"Krogh HB et al (2019) Methodological advantages and disadvantages of parallel and crossover randomised clinical trials on methylphenidate for attention deficit hyperactivity disorder: a systematic review and meta-analyses. BMJ Open 9(3):e026478","journal-title":"BMJ Open"},{"issue":"6","key":"458_CR35","doi-asserted-by":"publisher","first-page":"405","DOI":"10.2217\/pmt-2018-0054","volume":"8","author":"E Frisaldi","year":"2018","unstructured":"Frisaldi E, Shaibani A, Benedetti F (2018) Placebo responders and nonresponders: what\u2019s new? Pain Manag 8(6):405\u2013408","journal-title":"Pain Manag"},{"issue":"1","key":"458_CR36","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1002\/da.10134","volume":"19","author":"S Lee","year":"2004","unstructured":"Lee S, Walker JR, Jakul L, Sexton K (2004) Does elimination of placebo responders in a placebo run-in increase the treatment effect in randomized clinical trials? A meta-analytic evaluation. Depress Anxiety 19(1):10\u201319","journal-title":"Depress Anxiety"},{"issue":"10","key":"458_CR37","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1183\/09031936.93.06101449","volume":"6","author":"HA Hutchings","year":"1993","unstructured":"Hutchings HA, Eccles R, Smith AP, Jawad MS (1993) Voluntary cough suppression as an indication of symptom severity in upper respiratory tract infections. Eur Respir J 6(10):1449\u20131454","journal-title":"Eur Respir J"},{"issue":"1","key":"458_CR38","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1093\/ije\/dyh299","volume":"34","author":"AG Barnett","year":"2005","unstructured":"Barnett AG, van der Pols JC, Dobson AJ (2005) Regression to the mean: what it is and how to deal with it. Int J Epidemiol 34(1):215\u2013220","journal-title":"Int J Epidemiol"},{"issue":"4","key":"458_CR39","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1089\/acm.2012.0210","volume":"19","author":"H Bang","year":"2013","unstructured":"Bang H, Park JJ (2013) Blinding in clinical trials: a practical approach. J Altern Complement Med 19(4):367\u2013369","journal-title":"J Altern Complement Med"},{"issue":"10","key":"458_CR40","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1016\/j.jclinepi.2014.05.007","volume":"67","author":"S Bello","year":"2014","unstructured":"Bello S, Moustgaard H, Hrobjartsson A (2014) The risk of unblinding was infrequently and incompletely reported in 300 randomized clinical trial publications. J Clin Epidemiol 67(10):1059\u20131069","journal-title":"J Clin Epidemiol"},{"issue":"5","key":"458_CR41","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1080\/10543406.2017.1399898","volume":"28","author":"V Landsman","year":"2018","unstructured":"Landsman V, Fillery M, Vernon H, Bang H (2018) Sample size calculations for blinding assessment. J Biopharm Stat 28(5):857\u2013869","journal-title":"J Biopharm Stat"},{"issue":"13","key":"458_CR42","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1002\/(SICI)1097-0258(19960715)15:13<1421::AID-SIM266>3.0.CO;2-H","volume":"15","author":"KE James","year":"1996","unstructured":"James KE et al (1996) An index for assessing blindness in a multi-centre clinical trial: disulfiram for alcohol cessation\u2013a VA cooperative study. Stat Med 15(13):1421\u20131434","journal-title":"Stat Med"},{"issue":"2","key":"458_CR43","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.cct.2003.10.016","volume":"25","author":"H Bang","year":"2004","unstructured":"Bang H, Ni L, Davis CE (2004) Assessment of blinding in clinical trials. Control Clin Trials 25(2):143\u2013156","journal-title":"Control Clin Trials"}],"container-title":["Lung"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00408-021-00458-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00408-021-00458-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00408-021-00458-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T21:17:28Z","timestamp":1672867048000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00408-021-00458-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,19]]},"references-count":43,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["458"],"URL":"https:\/\/doi.org\/10.1007\/s00408-021-00458-2","relation":{},"ISSN":["0341-2040","1432-1750"],"issn-type":[{"value":"0341-2040","type":"print"},{"value":"1432-1750","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,19]]},"assertion":[{"value":"7 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None to declare. The author acts as a consultant on occasion to the pharmaceutical industry.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}